title: Superior protective and therapeutic effects of IL-12 and IL-18 gene-transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma.
abstract: Fusion vaccine of dendritic cells (DCs) and tumor cells has the advantage of inducing an immune response against multiple tumor Ags, including unknown tumor Ags. Using the liver metastasis model of C1300 neuroblastoma cells, we assessed the protective and therapeutic effects of fusion cells transduced with the IL-12 gene and/or the IL-18 gene. Improving the fusion method by combining polyethylene glycol and electroporation increased loading efficiency. In the A/J mice vaccinated with fusion cells modified with the LacZ gene (fusion/LacZ), IFN-gamma production and CTL activity increased significantly compared with that of DCs/LacZ, C1300/LacZ, or a mixture of the two (mixture/LacZ). With the transduction of IL-12 and IL-18 genes into the fusion cells (fusion/IL-12/IL-18), the level of IFN-gamma increased more than five times that of other fusion groups. In addition, NK cell activity and CTL activity increased significantly compared with that of mixture/LacZ, fusion/LacZ, DC/LacZ, or C1300/LacZ. In the protective and therapeutic studies of fusion cell vaccine, mice vaccinated with fusion/LacZ, fusion/IL-12, fusion/IL-18, or fusion/IL-12/IL-18 showed a significant decrease in liver metastasis and a significant increase in survival compared with mice given a mixture/LacZ, DCs/LacZ, or C1300/LacZ. In particular, the mice receiving fusion/IL-12/IL-18 vaccine showed a complete protective effect and the highest therapeutic effects. The present study investigates the improved loading efficiency of fusion cells and suggests that the introduction of IL-12 and IL-18 genes can induce extremely strong protective and therapeutic effects on liver metastasis of neuroblastoma.
authors.affiliation: Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-0003. iinuma@med.teikyo-u.ac.jp
authors.forename: Hisae
authors.initials: H
authors.lastname: Iinuma
authors.forename: Kota
authors.initials: K
authors.lastname: Okinaga
authors.forename: Ryoji
authors.initials: R
authors.lastname: Fukushima
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Inaba
authors.forename: Kota
authors.initials: K
authors.lastname: Iwasaki
authors.forename: Akira
authors.initials: A
authors.lastname: Okinaga
authors.forename: Ichiro
authors.initials: I
authors.lastname: Takahashi
authors.forename: Michio
authors.initials: M
authors.lastname: Kaneko
mesh_terms: D000818:Animals; D002459:Cell Fusion; D002460:Cell Line; D064987:Cell- and Tissue-Based Therapy; D003713:Dendritic Cells / Q000166:cytology* / Q000378:metabolism; D005260:Female; D015316:Genetic Therapy; D007114:Immunization; D018664:Interleukin-12 / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D020382:Interleukin-18 / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D007694:Killer Cells, Natural / Q000276:immunology / Q000378:metabolism; D008113:Liver Neoplasms / Q000235:genetics / Q000276:immunology / Q000556:secondary* / Q000628:therapy*; D051379:Mice; D009368:Neoplasm Transplantation; D009447:Neuroblastoma / Q000235:genetics* / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D010641:Phenotype; D013154:Spleen / Q000378:metabolism; D015996:Survival Rate; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000378:metabolism
chemical_list: D020382:Interleukin-18; D018664:Interleukin-12